Fresenius Makes Big Moves into China

Fresenius Makes Big Moves into China

Despite trade tensions between the United States and China, Fresenius Medical Care AG & Co. KGaA (NYSE: FMS) announced three major deals to expand there. The global dialysis company acquired majority shares in several dialysis centers and renal hospitals and has plans to build even more. Because of its enormous population of more than 1.4 billion people, China is a long-standing target market for American marketers. As Fresenius’ press release announcing these deals on December 5 noted, approximately 10.8% adults in China have chronic kidney disease, or 120 million people. The company paid an undisclosed amount for a 70% stake in Guangzhou KangNiDaiSi Medical Investment Co., Ltd.... Read More »

Fresenius Injects $5.1 Billion into its U.S. Pharma Unit

Fresenius Medical Care AG & Co. KGaA (NYSE: FMS) has been a busy deal maker. In 2016, its subsidiary Fresenius Helios bought the Spanish hospital chain Quironsalud for $6.5 billion, its Renal Care division acquired the rights to a chronic kidney disease drug for up to $282 million, and then a German-based cardiovascular medical device company for an undisclosed price. The company also picked up dialysis clinics throughout India and New York State, and other drug licenses in the meantime. Now, it has turned its attention to strengthening Fresenius Kabi, its sterile injectable medicines subsidiary. Biosimilars are a fast-growing segment within the pharmaceutical market,... Read More »